title: Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry).
abstract: Patients with mechanical prosthetic heart valves require long-term oral anticoagulant therapy (OAT). During the temporary interruption of OAT, bridging anticoagulant therapy with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) is recommended. This prespecified subgroup analysis from REGIMEN-a large, prospective, multicenter registry-compared UFH (n = 73) and LMWH (n = 172) as bridging anticoagulation in patients with mechanical heart valves on long-term OAT. Patient demographics and co-morbidities were generally similar between groups. There were more bileaflet valves in the LMWH group (67.4% vs 43.8%, p = 0.0005), but no differences in valve positions between groups. The LMWH group was less likely to undergo major surgery (33.7% vs 58.9%, p = 0.0002) and cardiothoracic surgery (7.6% vs 19.2%, p = 0.008), and to receive intraprocedural anticoagulants or thrombolytics (4.1% vs 13.7%, p = 0.007). Major adverse event rates (5.5% vs 10.3%, p = 0.23) and major bleeds (4.2% vs 8.8%, p = 0.17) were similar in the LMWH and UFH groups, respectively; 1 arterial thromboembolic event occurred in each group. More LMWH-bridged patients were treated as outpatients or discharged from the hospital in <24 hours (68.6% vs 6.8%, p <0.0001). Multivariate logistic analysis found no significant differences in major bleeds and major composite adverse events when adjusting for cardiothoracic or major surgery between groups. In conclusion, for patients with mechanical prosthetic heart valves on long-term OAT, mostly outpatient-based LMWH bridging therapy appears to be feasible for selected procedures, is as safe as UFH, and is associated with a low arterial thromboembolic rate.
authors.affiliation: Lovelace Medical Center, Albuquerque, New Mexico, USA. alex.spyropoulos@abqhp.com
authors.forename: Alex C
authors.initials: AC
authors.lastname: Spyropoulos
authors.forename: Alexander G G
authors.initials: AG
authors.lastname: Turpie
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Dunn
authors.forename: Scott
authors.initials: S
authors.lastname: Kaatz
authors.forename: James
authors.initials: J
authors.lastname: Douketis
authors.forename: Alan
authors.initials: A
authors.lastname: Jacobson
authors.forename: Hans
authors.initials: H
authors.lastname: Petersen
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D002170:Canada; D016009:Chi-Square Distribution; D016002:Discriminant Analysis; D017558:Elective Surgical Procedures; D005260:Female; D006350:Heart Valve Prosthesis; D006493:Heparin / Q000008:administration & dosage*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D016015:Logistic Models; D008297:Male; D011446:Prospective Studies; D012042:Registries; D014481:United States
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin